The Rett Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Rett Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rett Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued products.
GlobalData tracks 53 drugs in development for Rett Syndrome by 49 companies/universities/institutes. The top development phase for Rett Syndrome is preclinical with 27 drugs in that stage. The Rett Syndrome pipeline has 52 drugs in development by companies and one by universities/ institutes. Some of the companies in the Rett Syndrome pipeline products market are: Acadia Pharmaceuticals, Jazz Pharmaceuticals and Unravel Biosciences.
The key targets in the Rett Syndrome pipeline products market include Methyl CpG Binding Protein 2, Sigma Non Opioid Intracellular Receptor 1, and Cannabinoid Receptor 1.
The key mechanisms of action in the Rett Syndrome pipeline product include Methyl CpG Binding Protein 2 Activator with eight drugs in Phase II. The Rett Syndrome pipeline products include six routes of administration with the top ROA being Oral and seven key molecule types in the Rett Syndrome pipeline products market including Small Molecule, and Gene Therapy.
Rett Syndrome overview
Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III or the plateau, and Stage IV or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat, and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.
For a complete picture of Rett Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
